• Hypermorphic PLCg2 is independent of BTK activation.
Introduction
Chronic lymphocytic leukemia (CLL) is a clonally derived mature B-cell malignancy characterized by microenvironment dependence and constitutive activation of the B-cell receptor (BCR) pathway. [1] [2] [3] [4] Conventional therapy for fit, young patients includes chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. 5, 6 Outside of allogeneic stem cell transplantation, CLL is considered an incurable disease, and patients will eventually relapse following front-line therapy.
Recent advances in CLL disease biology confirm that the malignant cells receive heterogenic multicellular stimuli within the lymphoid tissues that subvert apoptosis and promote proliferation. 3, 7 Despite profound interpatient heterogeneity, the BCR pathway is a critical axis of CLL survival signaling, given its dominant role in nearly all cases of CLL. 4, 8 Mutations of the immunoglobulin heavy-chain variable region (IGVH) gene in CLL are associated with favorable responses, whereas unmutated subsets of CLL predict poor prognosis. 9 ,10 Current studies demonstrate anergic features in mutated CLL leading to downmodulation of surface immunoglobulin M (IgM), whereas unmutated CLL could transmit positive signaling and promote disease progression. 11 Hence, novel targeted therapies aimed to abrogate BCRintegral kinases have demonstrated marked clinical activity. 12 Ibrutinib is one such BCR-targeted therapy that covalently binds Bruton agammaglobulinemia tyrosine kinase (BTK) at cysteine 481. This prevents the critical LYN and SYK directed autophosphorylation of its Src homology 3 (SH3) domain; thereby preventing downstream activation of PLCg2 and, in turn, blocking downstream BCR signaling. Nevertheless, ibrutinib resistance due to acquired mutations in BTK and its direct downstream effector PLCg2 has been documented in a small number of cases. 13 Whereas the C481S mutation in BTK prevents ibrutinib covalent binding and thereby converts this agent to a less effective reversible inhibitor, 13 the previously identified R665W and L845F in PLCg2 have been only partially characterized and it remains unclear how these mutations confer molecular resistance. Although it is clear that these mutations are hypermorphic and augment BCR downstream signaling events regardless of BTK activity, we have shown previously that they do not induce autonomous PLCg2 signaling and still rely on BCR signaling events. Given that conventional activation of PLCg2 requires the cooperation of BTK, 14 the underlying molecular mechanisms that allow these PLCg2 mutations to bypass BTK inhibition remain an important question when considering new therapeutic strategies to combat ibrutinib resistance.
The BCR is composed of a tetrameric complex of Ig heavy and light chains, including Iga (CD79a) and Igb (CD79b), in which immunoreceptor tyrosine-based activation motifs are harbored. Upon BCR engagement, Src-family protein tyrosine kinases, primarily LYN, as well as SYK and BTK are activated by tyrosine phosphorylation upon receptor aggregation, 15 suggesting that BTK and PLCg2 are prerequisite molecules within the BCR activation pathway. In addition, defective IP 3 production and calcium mobilization have been described in SYK-deficient DT40 cells, 18 showing that SYK activation is indispensable for coupling BCR signaling to PLCg2 activation. The adaptor function of B-cell linker protein (BLNK) for recruiting both BTK and PLCg2 to the membrane compartment has been illustrated, 19 indicating a scenario in which SYK activates BTK leading to downstream PLCg2 activation. Until recently, the functional requirement of LYN in PLCg2 activation was still unclear. In regard to BCR activation, LYN-mediated Iga-Igb phosphorylation is essential for SYK activation. 20 The direct association between LYN and PLCg2 has been reported, 21 however, LYN-null DT40 cells reveal a differential response in calcium release and IP 3 production, 18 suggesting that LYN may jointly activate PLCg2 in coordination with SYK, BTK, and BLNK.
Given the direct clinical need, we sought to investigate the molecular pathogenesis of the acquired PLCg2 mutation in ibrutinib resistance. Ion torrent sequencing analysis from additional relapsed patients (in some patients without the coexistence of BTK mutations) confirmed the previously identified R665W mutation at PLCg2. The R665W mutation in PLCG2, which confers BTK independence and molecular resistance to ibrutinib was evaluated for its hypermorphic capacity to impel enhanced downstream signaling and Ca 21 flux in the setting of BCR stimulation. Furthermore, we observed the functional dependence of the R665W mutant on SYK and LYN, which cooperate with mutant PLCg2 to form a BTK bypass pathway. Together, our findings provide additional insight into the underlying mechanisms of ibrutinib resistance, and identify possible alternative therapies that target this aberration.
Materials and methods

Ion torrent analysis
DNA was extracted from cryopreserved isolated CLL cells using a DNA extraction kit (QIAamp DNA Mini Kit, Qiagen) according to the manufacturer's recommendations. DNA was quantified using a spectrophotometric method (NanoDrop 2000, Thermo Scientific) using the standard 260/280 optical density ratio. Analysis of the PLCG2 gene was performed using next-generation sequencing Ion Torrent platform and reagents from Life Technologies (Carlsbad, CA Final analysis of sequence data was performed using a combination of software: VariantCaller version 4.0-r76860, Ion Torrent IGV3.6.033, and Ion Reporter version 4.0. The NM002661.3 reference sequence was used for analysis. The entire length of sequences was reviewed manually using these programs to assess for deviation from reference sequence, and to evaluate the quality of sequence and the depth of coverage. The depth of coverage ranged from 1000 to 15 000 for different amplicons.
Reagents and antibodies
Antibodies against phospho-AKT (Ser473), AKT, phospho-extracellular signalregulated kinase (p-ERK)1/2 (Thr202/Tyr204), ERK1/2, phospho-PLCg2 (Tyr1217), PLCg2, phospho-SYK (Tyr525/526), BTK, phospho-Src/LYN, and LYN were obtained from Cell Signaling Technologies (Danvers, MA). Phospho-BTK (Tyr223) was obtained from Abcam (Cambridge, MA), SYK (N-19) from Santa Cruz Biotechnology (Santa Cruz, CA), and glyceraldehyde-3-phosphate dehydrogenase from Millipore (Billerica, MA).
PLCG2 cloning and cell culture
The chicken DT40 cell lines were provided by the RIKEN BioResource Center through the National Bio-Resource Project of the Ministry of Education, Culture, Sports, Science, and Technology, Japan. Cells were maintained in RPMI 1640 (Life Technologies, Grand Island, NY) with 2 mM L-glutamine, 10% fetal bovine serum, and 56 U/mL penicillin-streptomycin (Life Technologies). Human PLCG2 (BC007565.1) was cloned into a pBABE-Puro vector. Mutation in PLCG2 at R665W was derived using site-directed mutagenesis (QuikChange Lightning, Stratagene-Agilent Technologies, Santa Clara, CA). The pBABE-PLCG2 vectors were retrovirally introduced into cells. Cells stably expressing variant PLCg2 were selected out in the presence of 1 mg/mL puromycin for 2 weeks.
Immunoblot assays
Total lysate was extracted in M-PER Mammalian Protein Extraction Reagent (Pierce). Equivalent amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The blots were probed with the appropriate primary and horseradish peroxidase-conjugated secondary antibodies and developed with chemiluminescent substrate (Pierce), followed by detection using radiograph film and quantification using ImageJ software.
Calcium flux assays
Intracellular calcium change was measured by Calcium Assay Kit (BD Biosciences, San Diego, CA). Briefly, 5 3 10 4 cells in 50 mL complete RPMI medium were harvested in 96 wells half-area microplates. An equal volume of 1X Dye-loading Solution was added to each well and incubated for 1 hour at 37°C. After incubation at room temperature for another hour, calcium release was measured with the Beckman Coulter DTX880 Microplate Reader. After the acquisition to determine the baseline, 3 mg/mL anti-chicken IgM (SouthernBiotech, Birmingham, AL) was added to stimulate the cells. The areaunder-curve (AUC) was calculated and normalized to samples treated with dimethylsulfoxide (DMSO) alone; 1 mM ibrutinib for 1 hour followed by washout, 2.5 mM R406, 0.5 mM GS-9973, and 0.1 mM dasatinib were used.
Statistical methods
IP-One and calcium flux (AUC) comparisons between relevant conditions (eg, R665W vs wild-type [WT]
, ibrutinib vs DMSO) were performed using linear mixed effects models to account for correlations among replicates from the same subject/experiment; data from calcium flux experiments were log-transformed. For experiments with multiple comparisons, P values were adjusted using the Holm procedure to control overall type I error at .05. All analyses were performed using SAS/STAT software version 9.3 (SAS Institute Inc., Cary, NC).
Results
Missense point-mutation at R665W in PLCG2 was identified in relapsed patients
We have previously reported that relapse during ibrutinib therapy is associated with the acquisition of specific gene mutations. 13, 22 Besides C481S at BTK that directly impairs the targeting effect of ibrutinib, our previous studies identified somatically acquired PLCG2 variants and illustrated how those mutations augment downstream signaling in response to BCR engagement. Remarkably, R665W was recognized in (Table 1) . In all patients, the aberration was acquired during therapy, as deep sequencing of baseline samples did not reveal this mutation. Moreover, in 2 resistant patients, PLCG2 R665W exists without the BTK C481S mutation, indicating that this mutation can lead to resistance without cooperating BTK or other PLCG2 mutations. The detailed characteristics of patients who acquired the R665W mutation are summarized in Table 1 .
Hypermorphic PLCg2
R665W mutation is characterized by the ability to amplify BCR downstream signaling
The S707Y variant in human PLCG2 has been documented as an inherited mutation resulting in pathologic autoimmunity, suggesting that aberrations within SH2 loci of the auto-inhibitory domain may reinforce the enzymatic activity of PLCg2. 23 Given that R665W and S707Y are harbored at the same region (Figure 1 ), a similar capability was hypothesized. To evaluate the functional consequence of R665W, a chicken-derived PLCg2-deficient DT40 cell line was stably introduced with either WT or mutant human PLCg2 and stimulated by a-IgM. PLCg2-deficient DT40 fails to respond to anti-IgM stimulation, whereas the introduction of human PLCg2 can restore the signaling event (see supplemental Figure 1 on the Blood Web site). Consistent with previous results, 13 we found that PLCg2 R665W augments calcium flux, and this effect is resistant to ibrutinib treatment compared with WT (supplemental Figure 2) . Also, the R665W variant elicited robust downstream p-ERK activation after a-IgM stimulation (Figure 2A ), whereas the WT was sufficiently blocked by ibrutinib. PLCg2 cleaves its membrane-bound substrate to generate IP 3 and DAG. IP 3 causes calcium influx from the endoplasmic reticulum and triggers protein kinase C signaling. To examine whether PLCG2 R665W potentiates IP 3 production, 293T cells were stably introduced with either WT or PLCG2 R665W (supplemental Figure 3) . IP 3 production measured by the accumulation of IP 1 was elevated in PLCG2 R665W ( Figure 2B ), implicating that R665W mutation acquires hyperactivity by enhancing downstream signaling. These data suggest that the R665W, similar to the previously identified S707Y mutation, 24 confers hypermorphic activity upon BCR activation despite upstream BTK inhibition. Notably, the hypermorphic PLCg2 mutant fails to retain phosphorylation of Tyr 1217 after ibrutinib treatment despite preserving the capacity to elicit downstream signaling (Figure 2A ).
Hyperactivated PLCg2 no longer requires BTK in the BCR signaling pathway
Given that PLCg2 is the immediate downstream effector of BTK upon BCR activation, and our results indicate that ibrutinib does not inhibit downstream BCR signaling in the presence of mutated PLCg2, we sought to investigate the functional role of BTK in hypermorphic PLCg2. BTK-deficient DT40 cells were introduced with either WT or R665W PLCG2 followed by a-IgM stimulation. Consistent with previous results that BTK 2 DT40 expressing either WT PLCG2 or R665W mutant. Cells were treated with 0.5 mg/ml a-IgM for 15 minutes; 1.0 mM ibrutinib was pretreated for 1 hour followed by washout; and 0.5 mM GS-9973 or 2.5 mM R406 was treated.
cells triggered only modest calcium flux, and PLCG2 R665W significantly enhanced BTK-independent calcium release ( Figure 2C ) as well as downstream ERK activation ( Figure 2D ), suggesting that this hypermorphic PLCg2 mutant functionally bypasses BTK and promotes downstream activation of the BCR pathway.
Pharmacologically targeting SYK and LYN can abrogate hypermorphic PLCg2
Since BTK is not required for triggering activation of PLCG2 R665W , we hypothesized that specific upstream kinases, which are attributed to PLCg2 activation may still be required, and that targeting these kinases could represent an alternative strategy for the treatment of acquired ibrutinib resistance. Previous studies confirm that SYK-deficient DT40 cells display abolished IP 3 or Ca 21 production after BCR engagement. 18 Furthermore, SYK has been shown to directly participate in PLCg2 activation via interaction with BLNK, 8 implicating SYK as a possible therapeutic target. To assess this hypothesis, SYK inhibitors were tested against the PLCg2 mutant. GS-9973 is one of the SYK inhibitors undergoing clinical evaluation for patients with relapsed or refractory hematologic malignancies. R406 is the active derivative of the prodrug fostamatinib that has been assessed in patients with lymphoma or rheumatoid arthritis. Optimal doses of these agents were assessed in DT40 cells to sufficiently abrogate BCR activation without inducing cytotoxicity (supplemental Figure 4) . Remarkably, single agent treatment of either GS-9973 or R406 sufficiently impeded the hypermorphic calcium release and downstream ERK activation in PLCg2-deficient DT40 cells expressed PLCG2
R665W
, in contrast to ibrutinib, which is only effective in WT ( Figure 3A-B) . Similar results using combinational treatments compared with the SYK inhibitor alone was observed, demonstrating that SYK proximately functions to BTK/ PLCg2. These data suggest a new therapeutic role for SYK-targeting in CLL patients with acquired hypermorphic PLCg2 R665W . The BCR also utilizes Src-family protein tyrosine kinases like LYN to regulate downstream effectors. Although the functional correlation between LYN and PLCg2 has not been fully established, reduced activation of PLCg2 and Ca 21 production has been characterized in LYN-deficient B cells leading to the assumption that hypermorphic PLCg2 may be dependent upon LYN activation. 18 To test this hypothesis, we used dasatinib, a known Src and LYN inhibitor. Our data reveal that PLCG2 R665W -induced calcium release and downstream activation could be attenuated by dasatinib (Figure 4A-B ). These findings demonstrate the therapeutic potential of LYN inhibition in patients with ibrutinib-resistant PLCG2 mutations, as well as LYN's involvement in regulating PLCg2 activation.
SYK and LYN targeting blocks BCR signaling in ibrutinib-resistant CLL samples
To investigate the effects of targeting SYK and LYN, CLL cells from 3 ibrutinib resistant patients bearing PLCG2
R665W were tested. Although modest elevation of Ca 21 influx in nonresistant samples was In the treatment settings, 1.0 mM ibrutinib was pretreated for 1 hour followed by washout; 0.1 mM dasatinib was used. *P , .05; ***P , .001; NS 5 P . .05. (B) Downstream signaling was accessed in PLCg2
DT40 expressing either WT human PLCg2 or R665W mutant. Cells were treated with 0.5 mg/ml a-IgM; 1.0 mM ibrutinib was pretreated for 1 hour followed by washout; and 0.1 mM dasatinib was used.
measured, all 3 ibrutinib-resistant CLL samples induced robust Ca 21 release upon stimulation ( Figure 5A ), and this effect was significantly inhibited by dasatinib, GS-9973, or R406 treatment ( Figure 5B ). Moreover, SYK or LYN inhibition reduced Ca 21 flux more effectively than ibrutinib in these resistant samples, reducing overall activation to levels within the range of nonresistant samples ( Figure 5B ). To gain primary molecular insight, we examined downstream activation upon BCR engagement in baseline or relapse setting in samples obtained from a single patient who developed ibrutinib resistance (patient #2 in Table 1 ). Although stronger induction of p-ERK is ineffectively suppressed by ibrutinib in the relapse sample, dasatinib, GS-9973, or R406 successfully reversed downstream signaling activation ( Figure 5C ). Together, our results verify both SYK and LYN as therapeutic targets in patients with acquired PLCg2 hypermorphic mutations. were measured, and 5E6 cells per well in 96-half well microplates were stimulated with 10 mg/ml a-IgM at 37°C for 15 minutes, and then measured by BD Calcium Assay Kit. The data represent AUC from 7 and 12 replicates in resistant and nonresistant samples, respectively; 1.0 mM ibrutinib was pretreated for 1 hour followed by washout. (B) The data represents calcium release by 3 individual relapse CLL (R) or the mean of 12 nonresistant samples (NR) stimulated with 10 mg/ml a-IgM in the presence of 0.5 mM GS-9973, 2.5 mM R406, or 0.1 mM dasatinib; 1.0 mM ibrutinib was pretreated for 1 hour followed by washout. ***P , .001. (C) The downstream phospho-protein activation was accessed in CLL cells from a single patient (patient #2 in Table 1 ) in the baseline or relapse setting. The detailed information of the 3 relapsed CLL patient samples analyzed here are listed in Table 1 .
Discussion
Although microenvironment-derived CLL survival and proliferation stimuli are multifactorial, the BCR plays a critical role in driving disease progression; hence, ibrutinib has demonstrated exceptional clinical results in CLL. Nonetheless, relapses have been observed and understanding the molecular pathways that confer ibrutinib resistance is of the utmost priority in determining the treatment scheme in these patients. Given the predominant effect of ibrutinib in suppressing BCR signaling, the resistant mechanisms are speculated to emerge within this signaling pathway. In this study, extended from our previous report, genetic aberrations at PLCG2 are further elucidated in relapsed patients. Our data thoroughly characterize the competency of the R665W mutation to trigger downstream BCR signaling independent of BTK upon anti-IgM stimulation and explains why these patients are resistant to ibrutinib. We show here, that the proximal effectors SYK and LYN collaborate to activate mutated PLCg2 regardless of BTK activation. Moreover, pharmacologically targeting either SYK or LYN can overcome persistent survival signaling ( Figure 6 ). Together, these data augment the understanding of mutated PLCg2-mediated ibrutinib resistance, and suggest alternative approaches to overcome the genetic abnormalities.
Similar to drug resistances that result from hampered affinity, mutations in BTK have been recognized in patients who relapsed on ibrutinib. These findings further support the prominent role of BCRmediated CLL progression. Intriguingly, BTK remains normal in a subset of relapsed patients with PLCG2 R665W , suggesting that PLCG2 R665W is sufficient to induce ibrutinib resistance. Remarkably, the aberration in PLCg2 appears to be somatically acquired only after long-term ibrutinib treatment, suggesting that this clone evolved under continuous pressure from this irreversible agent. Indeed, although subgroups of CLL drive toward anergy, differential capacity of BCR signaling has been demonstrated to correlate with surface IgM expression. 25 Although comparable sIgM was detected in DT40 expressing PLCg2 R665W , CLL with this hypermorphic aberration may enhance the survival advantage and gain access to tissue environment. 25 PLCg2 activity is correlated with tyrosine phosphorylation at 753, 759, 1197, and 1217. 26, 27 On a molecular level, the phospholipase activity is repressed by the auto-inhibitory region encompassed within X-and Y-box domains. Recent studies indicate the crucial function of carboxyl-terminal SH2 in the regulatory element in suppressing PLCg2 activity. 26 The inherited S707Y mutation at this region has been reported to confer a hypermorphic effect and leads to an auto-inflammatory response. 24 Consistent with this notion, R665W residing within this region appears to elicit an analogous mechanism to impose enzymatic activity via releasing the catalytic domain of PLCg2 through a peptide conformation change. Nevertheless, direct phosphorylation sites triggered by BTK, such as Tyr1217, remains functionally inhibited in the presence of ibrutinib despite hyperactive downstream signaling events induced by mutated PLCg2 (Figure 2A) , affirming the activation of mutant PLCg2 is discrete from BTK activity. Although previous studies have confirmed the indispensable role of BTK for PLCg2 activation, 14 mutated PLCg2 may shift the functional dependency to other proximal kinases. Moreover, PLCg2 activation also requires membrane docking; a process recruited by BLNK (SLP-65), 28 suggesting the possibility that mutated PLCg2 may be retained at the plasma membrane through positive modulation by BLNK. In regard to proximal kinases that initiate PLCg2 activation, our data shows that SYK and LYN are essential for the activation of mutated PLCg2. Considering membrane localization requires interactions between Pleckstrin homology domain at PLCg2 and phosphatidylinositol lipids within the plasma membrane, 29, 30 PI3K inhibitors were also evaluated as potential alternatives. Nevertheless, our data indicates neither idelalisib nor IPI-145, inhibitors of PI3K p110d and/or p110g subunits in clinical use, could abrogate PLCG2 R665W -mediated downstream signaling despite AKT inhibition (supplemental Figure 5) .
R665W aberration at PLCg2 is in close proximity to identified phosphorylation sites, Tyr753 and Tyr 759, raising the possibility that the mutation may lead to conformational change of PLCg2, amplifying its catalytic function upon stimulation regardless of the phosphorylation status at these tyrosine residues. However, it is also unknown whether the hypermorphic mutation could acquire higher affinity to SYK, LYN, or BLNK, leading to sustained activity after stimulation.
It is important to note that at most 45% of the variant frequencies are at R665W; however, the frequency of this aberration is variable when measured in peripheral blood samples from relapsed CLL patients, denoting that resistant clones bearing PLCG2 R665W might enrich within bone marrow or lymphoid organs. Likewise, advanced sequencing technologies are in demand to certify if the aberration existed with extremely low frequency at baseline. Alternatively, cooperative scenarios leading to resistance may also contribute to relapse settings. Conforming to this, BTK or other PLCG2 mutations were concurrently observed in relapsed patients with R665W (data not shown), suggesting additional aberrations at this signaling axis may synergistically contribute to CLL progression. Further studies will be required to fully elucidate this. Finally, despite the elusive origins of these abnormalities, work is underway to scrutinize the functional roles of diverse aberrations in PLCg2. 
